Evidence map›Paper›PMID 35607843›Full record

Observational studyActa neurologica Scandinavica2022

Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study.

Alfonso Fasano, Victor S C Fung, Klaus Seppi, Zvezdan Pirtosek, Annamária Takáts, Ali Alobaidi, Koray Onuk, Lars Bergmann, Juan Carlos Parra, Bulent Elibol

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Acta neurologica Scandinavica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Observational
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 7 countries.

Alfonso FasanoEdmond J Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, ON, Canada.
Victor S C FungMovement Disorders Unit, Westmead Hospital, Westmead, NSW, Australia.
Klaus SeppiMedical University Innsbruck, Innsbruck, Austria.
Zvezdan PirtosekUniversity Medical Center Ljubljana, Ljubljana, Slovenia.
Annamária TakátsNeurological Clinic of Semmelweis University, Budapest, Hungary.
Ali AlobaidiAbbVie Inc., North Chicago, IL, USA.
Koray OnukAbbVie Inc., North Chicago, IL, USA.
Lars BergmannAbbVie Inc., North Chicago, IL, USA.
Juan Carlos ParraAbbVie Inc., North Chicago, IL, USA.
Bulent ElibolDepartment of Neurology, Hacettepe University Hospitals, Ankara, Turkey.
AbbVie (United States) · USHacettepe University Hospital · TRInnsbruck Medical University · ATKrembil Foundation · CALjubljana University Medical Centre · SISemmelweis University · HUWestmead Hospital · AU

Funding

AbbVie
6 · The paper itself

Abstract

objectivesIn the absence of widely accepted criteria, determining when a patient with Parkinson's disease (PD) may benefit from more advanced treatments such as device-aided therapy (DAT) so far remains a matter of physician judgment. This analysis investigates how classification of PD varies across countries relative to measures of disease severity. MATERIALS AND

methodsThe OBSERVational, cross-sEctional PD (OBSERVE-PD) study included consecutive patients with PD at centers that offer DATs in 18 countries. In this subgroup analysis, we explore intercountry differences in identification of advanced versus non-advanced PD based on physician's clinical judgment, symptoms assessed using Delphi consensus criteria, use of DAT, motor and non-motor symptoms, and caregiver support. Demographic and clinical characteristics were obtained through review of medical records.

resultsOverall, 1342 of 2615 patients (51.3%) were assessed by physicians as having advanced PD. The proportion of patients in different countries identified as having advanced PD (24.4-82.2%) varied. In 15 of 18 countries, a greater proportion of patients with advanced PD, according to select Delphi criteria, were identified by physicians as having advanced PD than with non-advanced PD. There was a wide variability across countries in the proportion of patients with no dyskinesia, disabling dyskinesia, dyskinesia pain, and non-motor symptoms who were identified by physicians as having advanced versus non-advanced PD.

conclusionsThe proportion of patients identified with advanced PD symptoms varies widely across countries, despite differences on the patients' profiles, indicating a need for objective diagnostic criteria to help identify patients who may benefit from DAT.

Indexed as

Parkinson DiseaseAntiparkinson AgentsCarbidopaCross-Sectional StudiesDrug CombinationsGelsHumansLevodopaSeverity of Illness IndexAntiparkinson AgentsCarbidopaDrug CombinationsGelsLevodopaapomorphinedeep-brain stimulationDelphi studyinfusion pumpintraintestinal infusionlevodopa-carbidopa drug combinationParkinson's disease

Identifiers

PMID35607843
PMCPMC9541702
OpenAlexW4282917800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.